Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen–age volume

Yuan-Fei Lu, MD\textsuperscript{a}, Qian Zhang, MD\textsuperscript{a}, Hai-Yan Chen, MD\textsuperscript{a}, Jie-Yu Chen, MD\textsuperscript{a}, Yao Pan, MD\textsuperscript{a}, Cong-Cong Xu, MD\textsuperscript{b}, Jian-Xia Xu, MD\textsuperscript{c},* Ri-Sheng Yu, MD, PhD\textsuperscript{a,2}

Abstract
To improve the detection of prostate cancer (PCa) by combining the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) and prostate-specific antigen–age volume (PSA–AV), especially among those in gray zone with PI-RADS v2 score 3 or serum total prostate-specific antigen (tPSA) 4 to 10ng/mL.

The 357 patients were enrolled in this study. The PI-RADS v2 scoring system was used to represent characteristics on multiparametric magnetic resonance imaging (mpMRI). PI-RADS v2 score 3 or tPSA 4 to 10ng/mL were defined as the gray zone in detecting PCa. The formula equates to the patient age multiplied by the prostate volume, which is divided by the tPSA level. Univariate and multivariate analyses were done to ascertain significant predictors of prostate cancer.

In all, 174 (48.7%) were benign prostatic hyperplasia, 183 (51.3%) had PCa. The results showed that PI-RADS v2, tPSA, and PSA–AV were significant independent predictors of prostate cancer. PI-RADS v2 score ≥ 3 could detect PCa with rate of 82.1%. Serum tPSA ≥ 10ng/mL could detect PCa with rate of 66.2%, PSA density (PSAD) ≥ 0.15ng/mL/cc with rate of 62.8%, and PSA–AV ≤ 250 with rate of 83.5%. Combining with PSA–AV ≤ 250, patients those with tPSA 4 to 10 ng/mL could improve the detection from 36.0% up to 81%, those with PI-RADS v2 score 3 from 28.6% up to 60.0%.

PI-RADS v2 and PSA–AV are faithful variables for detecting PCa. And for patients, those in gray zones of PI-RADS v2 and tPSA, PSA–AV can improve detection rate of PCa.

Abbreviations: DWI = diffusion weighted imaging, mpMRI = multiparametric magnetic resonance imaging, PCa = prostate cancer, PI-RADS v2 = The Prostate Imaging Reporting and Data System version 2, PSA–AV = prostate-specific antigen–age volume, PSAD = prostate-specific antigen density, tPSA = total prostate-specific antigen, TRUS = transrectal ultrasound.

Keywords: MRI, PI-RADS score, PSA, volume

1. Introduction
Prostate cancer (PCa) is the second most common cancer worldwide, and its death rate ranks sixth in males\textsuperscript{[1]} and the number of males diagnosed as PCa in Asia is dramatically increasing.\textsuperscript{[2]} Prostate-specific antigen (PSA), as a classical parameter, is widely used to monitor PCa\textsuperscript{[3]} and the cut-off point, 4ng/mL, indicates the increasing risk of PCa.\textsuperscript{[4]} However, it is prone to lead to over diagnosis and overtreatment owing to its lack of accuracy. For people with PSA levels between 4 and 10 ng/mL, which is a gray zone, only a quarter suffer from PCa.\textsuperscript{[5]} Thus, reliable parameters are needed to improve the accurate diagnosis of PCa.

Multiparametric magnetic resonance imaging (mpMRI) can identify the presence of PCa and it is suggested that mpMRI is helpful in improving the diagnosis of PCa.\textsuperscript{[6]} In 2014, the Prostate Imaging-Reporting and Data System Version 2 (PI-RADS v2) was published to establish a globally agreed upon criterion regarding PCa diagnosis on imaging. It classifies all imaging characteristics into 5 points of diagnosis PCa: 1 point, which indicates very low probability; to 5 points, which indicates very high probability.\textsuperscript{[7]} PI-RADS v2 has not provided the follow-up management for lesions of score 3. It is reported in several researches that the PI-RADS v2 score 3 has no connection with clinically significant PCa,\textsuperscript{[8]} while some report that score 3 is a characteristic of the indeterminate zone detection of PCa.\textsuperscript{[9]}

In order to improve the diagnosis of PCa in these gray zones, this study makes use of prostate-specific antigen–age volume (PSA–AV). PSA–AV is a parameter derived from a simple combination of total prostate-specific antigen (tPSA), age, and prostate volume.\textsuperscript{[10]} The formula equates to the patient age multiplied by the prostate volume, which is divided by the tPSA.

Editor: Giandomenico Rozello.
Y-FL and QZ contributed equally.

This study was supported by grants from the Zhejiang Medical and Health Science and Technology Plan Project (2019329728).

The authors report no conflicts of interest.

\textsuperscript{a} Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, \textsuperscript{b} Department of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang Chinese Medical University, Hangzhou, China.

\textsuperscript{c} Correspondence: Ri-Sheng Yu, Department of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jie-Fang Road, Hangzhou, 310009, China (e-mail: rsheng-yu@zju.edu.cn); Jian-Xia Xu, Department of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang Chinese Medical University, 318 Chao-Wang Road, Hangzhou, 310005, China (e-mail: xjx129@163.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Medicine (2019) 98:26(e16289)
Received: 16 January 2019 / Received in final form: 16 May 2019 / Accepted: 10 June 2019
http://dx.doi.org/10.1097/MD.0000000000016289
level ( PSA-AV = volume x age/tPSA). PSA-AV scores show its capacity in predicting the absence or presence of PCa. Furthermore, the role of PSA-AV in the Chinese population is proved preliminarily, especially in younger patients. Therefore, this study investigates the ability of PSA-AV to detect PCa in the gray zone with PI-RADS v2 score 3 or serum tPSA 4 to 10 ng/mL.

2. Materials and methods

2.1. Patient population

This is a retrospective study performed at our institution. Institutional review board approval and informed consent were obtained. Between January 2014 and December 2017, a total of 1720 patients underwent prostate MRI at this institution. Excluding cases were based on the following items:

1. Prostate mpMRI, patients previously accepted treatment, (drug treatment, biopsies, or surgical therapy);
2. Serum examinations were missing or performed after treatment;
3. The time interval between MRI and the following transrectal ultrasound (TRUS)-guided 12-core prostate biopsy was more than 2 weeks. Finally, 357 patients were eligible for the study.

2.2. MRI

All patients were performed MR examinations on 3.0T GE equipment (DISCOVER MR750 GEH,GEH), using a multichannel vitro coil. Turbo spin-echo T2-weighted imaging (repetition time msec/echo time msec, 4291/95, 9.9-101.2; section thickness, 3 to 4 mm; intersection gap, 0 mm; field of view, 200 x 200 mm; matrix, 352 x 352), diffusion-weighted imaging (DWI, repetition time msec/echo time msec, 4000/57-59; section thickness, 3-4 mm; intersection gap, 0 mm; field of view, 370 x 370 mm; matrix, 128 x 160), apparent diffusion coefficient and dynamic contrast-enhanced (repetition time msec/echo time msec, 4,3/1.9-2.0; section thickness, 3-4 mm; intersection gap, 0 mm; field of view; 320 x 320 mm; matrix, 320 x 224; does 0.1 mmol/kg standard gadolinium-based contrast agent; injection rate: 2-3 cc/sec) were done. The b value of DWI was 1500 s/mm².

2.3. Pathology

The prostate biopsies were taken transrectally using an automatic biopsy gun and a 12+X-G needle under ultrasound-guidance (TRUS, 6 in the peripheral zone and 6 in the transitional zone, X in suspicious zone). TRUS-guided biopsy combined TRUS-guided targeted biopsy with cognitive MRI fusion-guided targeted biopsy. Prostate surgery included radical prostatectomy and transurethral resection of the prostate. The specimens which were obtained in ways above were assessed by experienced pathologists.

2.4. Statistical analyses

The imaging was read by a senior radiologist who was trained through PI-RADS v2 criterion and blinded to clinical data to decrease bias. T2-weighted imaging and DWI were the dominant determining sequences for transition zone and the peripheral zone, respectively. Prostate volume was measured in T1-weighted imaging and the formula equated to the length multiplied by the width by height by 0.52. According to PSA level, patients were divided into 3 groups: ≤4 ng/mL as group 1; 4 to 10 ng/mL as group 2; and >10 ng/mL as group 3. All data were analyzed in SPSS 23.0 and P <0.05 was thought to have statistical significance. PSA, PSA-AV, age, prostate volume, and PI-RADS v2 were included to predict PCa. Univariate and multivariate analyses were done to ascertain significant predictors of prostate cancer. Detection rate was used to evaluate the diagnostic performance. Receiver operating characteristic analysis was done to find the suitable cut-off point of PSA-AV score to detect PCa.

3. Results

Patients characteristics were presented in Table 1. The media and interquartile range relating to age, tPSA, volume, and PAV-AV were 68 (63-74) years, 11.06 (6.79-21.34) ng/mL, 49.18 (30.70-57.62) mL, and 357 (121-453), respectively. According to the PSA level, 6.4% (23/357) belonged to group 1 (tPSA ≤4 ng/mL), 38.1% (136/357) belonged to group 2 (tPSA between 4 and 10 ng/mL), 55.5% (198/357) belonged to group 3 (tPSA >10 ng/mL). The number of PI-RADS v2 score 1-2 were 154; score 3 was 35; scores 4 to 5 were 168. Moreover, the cut-off line at 230 of PSA-AV was the critical value necessary to reach the maximum Youden index. The number of patients whose PSA-AV ≤230 were 164.

Of the 357 patients involved in the study, 48.7% (174/357) were benign prostatic hyperplasia and 51.3% (183/357) were prostate cancer. Among patients of PCa, 18.6% (34/183) had a Gleason score of 4, 40.4% (74/183) had a Gleason score of 7 and 41.0% (75/183) had a Gleason score of 8 to 10.

The pathologic result stratified by tPSA, prostate-specific antigen density (PSAD), PSA-AV, and PI-RADS v2 are described in Figure 1. The detection rate of PCa among tPSA group 1 to 3 were 13.0% (3/23), 36.0% (49/136), and 82.4% (131/159). The detection rate of PCa using the PI-RADS v2 score of 1 to 2, 3, 4 to 5 were 29.4% (10/35), 28.6% (10/35), and 82.1% (138/168), respectively.

Table 1

| Variable | Value |
|----------|-------|
| Age, yr  | 68    |
| tPSA, ng/mL | 11.06 |
| PSA-AV   | 357   |
| Volume, mL | 49.18 |
| Gleason score | 145.0 |
| BPH      | 174   |
| Score 6  | 34    |
| Score 7  | 74    |
| Score 8  | 47    |
| Score 9  | 22    |
| Score 10 | 6     |
| PI-RADS2 score | 154 |
| 1–2     | 154   |
| 3       | 35    |
| 4–5     | 168   |

BPH=benign prostatic hyperplasia, IQR=interquartile range, PI-RADS v2=The Prostate Imaging-Reporting and Data System Version 2, tPSA=total prostate-specific antigen.
PSA–AV, PSAD, tPSA, and PI-RADS v2 were significant predicative parameters for PCa in univariate logistic regression analysis (Table 2). The multivariate logistic regression analysis suggested that PSAD, PI-RADS v2, and PSA–AV were independent predictors of PCa (Table 2).

In the transition zone, PSA–AV \( \leq 250 \) could detect PCa with rate of 67.3\% (33/49), and PSAD \( \geq 0.15\) ng/mL/cc with rate of 38.5\% (42/109). In the peripheral zone, PSA–AV \( \leq 250 \) could detect PCa with rate of 90.4\% (104/115), and PSAD \( \geq 0.15\) ng/mL/cc with rate of 79.4\% (127/160) (Tables 3). In the peripheral zone, the detection rate was not as satisfactory, compared to the 92.4\%, compared to the 57.1\% of PSA–AV >250. Likewise, in this subgroup, group 3 of tPSA had detection rate of 89.8\%, compared to the 66.7\% of those in group 2 of tPSA (Fig. 2A). The function of PSAD in detecting PCa in subgroups of tPSA and PI-RADS v2 was presented in Figure 2B.

4. Discussion

The study revealed that PI-RADS v2, PSAD, PSA–AV, and tPSA were the significant predictors for PCa. PI-RADS v2 itself was efficient in diagnosing PCa. When the PI-RADS v2 score 4 was supposed to be positive, the detection rate was quite satisfactory, up to 82.1\%. This result was similar to previous researches.\cite{12, 13, 14} PI-RADS v2 score 2 rarely yield to PCa, while the connection between PI-RADS v2 score 3 as well as the presence of PCa was uncertain.\cite{9, 15} In this situation, other parameters may be needed to decrease false-positives and increase the cancer detection rate.\cite{16} Furthermore, the PI-RADS v2 score in subgroups according to tPSA and PSA–AV represent different diagnostic accuracy. Those patients in higher tPSA or lower PS–AV group, lower PI-RADS v2 score also detected the PCa more effectively (Fig. 2).

The serum tPSA is the most useful cancer marker in predicting PCa.\cite{17} However, tPSA has its limitations in clinical experience as it is influenced by a variety of factors, including age, volume, medicine, and others. In previous researches, the specificity of tPSA in 4 to 10 ng/mL was not very high,\cite{18, 19} which lead to numerous unnecessary biopsies. Some researches confirmed that age was a significant variable associated with serum tPSA.\cite{20, 21} The baseline serum tPSA for detecting PCa was increasing in parallel with age. Furthermore, the prostate volume, based on MRI, could improve the effectiveness of tPSA for predicting PCa.\cite{22, 23} PSA–AV, incorporating age, prostate volume and serum tPSA, is a parameter to predict PCa, which was introduced by Patel et al. Wu YS et al had tested the PSA–AV performance in predicting PCa and proved that it was an effective variable in diagnosing PCa, especially in young patients and those with small prostate volumes.

**Table 2**

|          | Univariate analysis | Multivariate analysis |
|----------|---------------------|-----------------------|
|          | OR                  | 95% confidence interval | P   | OR                  | 95% confidence interval | P   |
|          |         | Lower | Upper |          |         | Lower | Upper |          |         | Lower | Upper |          |         | Lower | Upper |          |         | Lower | Upper |          |         | Lower | Upper |          |         | Lower | Upper |          |         |
| PI-RADS v2 |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |
| 1–2      | 1.36    | 0.596 | 3.102 | .465      | 1.367 | 0.487 | 3.836 | <.001     | 1.367 | 0.487 | 3.836 | <.001     |
| 3–5      | 16.64   | 9.061 | 26.995 | <.001     | 3.046 | 2.13  | 4.354 | <.001     | 3.046 | 2.13  | 4.354 | <.001     |
| PSA      |         |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |
| <0.15    | 8.944   | 4.794 | 16.646 | .044      | 5.136 | 2.189 | 12.053 | <.001     | 5.136 | 2.189 | 12.053 | <.001     |
| ≥0.15    |         |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |
| PSA–AV   |         |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |
| >250     | 16.215  | 9.553 | 27.524 | <.001     | 8.964 | 3.485 | 23.055 | <.001     | 8.964 | 3.485 | 23.055 | <.001     |
| ≤250     |         |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |
| tPSA     |         |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |          |        |       |       |
| group 1  | 3.755   | 1.062 | 13.277 | .022      | 4.528 | 1.053 | 19.46  | .042      | 4.528 | 1.053 | 19.46  | .042     |
| group 2  | 13.035  | 3.739 | 45.436 | <.001     | 1.26  | 0.506 | 3.134  | .062      | 1.26  | 0.506 | 3.134  | .062     |
| group 3  | 0.965   | 0.955 | 0.976  | <.001     | 0.966 | 0.95  | 0.982  | <.001     | 0.966 | 0.95  | 0.982  | <.001     |
| age      | 1.08    | 1.05  | 1.11   | <.001     | 1.134 | 1.087 | 1.183  | <.001     | 1.134 | 1.087 | 1.183  | <.001     |

**PI-RADS v2** = The Prostate Imaging Reporting and Data System version 2, **PSAD** = prostate-specific antigen density, **PSA–AV** = prostate-specific antigen–age volume.
To the best of our knowledge, this study is the first research to assess the PSA–AV in the gray zone with PI-RADS v2 score 3 or serum tPSA 4 to 10ng/mL. The result revealed that of patients in the gray zone, the PSA–AV score was useful in predicting the presence of PCa. Though a PI-RADS v2 score ≤ 3 suggested lower probabilities of PCa, our study showed that a PSA–AV ≤ 250 was helpful in raising the detection rate in this range. The same probabilities of PCa, though a PI-RADS v2 score 3 or serum tPSA was ≤ 250 and the tPSA was >4 ng/mL, it would be favorable to organized follow-up therapeutic measures. Of the PI-RADS v2 score 3, the gray zone is used to detect PCa in clinical experiences, with an associated detection rate of 28.6%. For these patients, the risk of PCa decreases when detecting PCa in clinical experiences, with an associated detection rate of 28.6%. For these patients, the risk of PCa decreases when the PI-RADS v2 score exceeds 4, it yields to PCa highly unless the tPSA ≤ 4ng/mL. In this way, dividing PI-RADS v2 into more detailed subgroups may be helpful for urologist when making clinical decisions.

The study also discussed the efficiency in detecting PCa of PSAD and PSA–AV. Comparing with PSAD, the variable PSA–AV attached importance to age because the cutoff point of predicting PCa of serum tPSA increased with age.[26,27] Both PSAD and PSA–AV showed stronger capacity in assessing PCa in patients into different risk grades according to their PI-RADS v2 score, serum tPSA and PSA–AV. For patients of PI-RADS v2 scores 1 to 2, if the PSA–AV was ≤ 250 and the tPSA was >4 ng/mL, it would be favorable to organized follow-up therapeutic measures. Of the PI-RADS v2 score 3, the gray zone is used to detect PCa in clinical experiences, with an associated detection rate of 28.6%. For these patients, the risk of PCa decreases when the PI-RADS v2 score >250 or the PSA–AV >42.9. In this way, dividing PI-RADS v2 into more detailed subgroups may be helpful for urologist when making clinical decisions.

To the best of our knowledge, this study is the first research to assess the PSA–AV in the gray zone with PI-RADS v2 score 3 or serum tPSA 4 to 10ng/mL. The result revealed that of patients in the gray zone, the PSA–AV score was useful in predicting the presence of PCa. Though a PI-RADS v2 score ≤ 3 suggested lower probabilities of PCa, our study showed that a PSA–AV ≤ 250 was helpful in raising the detection rate in this range. The same situation in patients of tPSA levels between 4 and 10ng/mL. By evaluating PSA–AV in the presence of PCa, it could finely improve the problem associated with tPSA: sensitivity in assessing PCa that was relatively low.

Though the PI-RADS v2 is a standard criterion for detecting PCa, it only assesses the appearances on MRI but ignores the capacity of clinical parameters.[24,25] In this study, a crosstab was drawn to evaluate the risk of PCa in different subgroups, and detection rates were calculated. Based on our study, we classified

| Table 3 | Prostate cancer detection stratified by PI-RADS v2 score, tPSA, or PSA–AV. |
|---------|--------------------------------------------------------------------------------|
| Prostate cancer detection rate (%) | |
| PI-RADS v2 | PSA–AV | tPSA (ng/mL) | PSAD (ng/mL/cc) | PSA–AV |
| 1–2 | 25.8 | 28.6 | 82.1 | 23.8 |
| 3 | 0.0 | 28.8 | 82.1 | 23.8 |
| 4–5 | 0.0 | 36.0 | 82.4 | 23.8 |

PI-RADS v2 = the Prostate Imaging Reporting and Data System version 2; PSA–AV = prostate-specific antigen–age volume; tPSA = total prostate-specific antigen; PSAD = prostate-specific antigen density; PSA = total prostate-specific antigen.

To the best of our knowledge, this study is the first research to assess the PSA–AV in the gray zone with PI-RADS v2 score 3 or serum tPSA 4 to 10ng/mL. The result revealed that of patients in the gray zone, the PSA–AV score was useful in predicting the presence of PCa. Though a PI-RADS v2 score ≤ 3 suggested lower probabilities of PCa, our study showed that a PSA–AV ≤ 250 was helpful in raising the detection rate in this range. The same situation in patients of tPSA levels between 4 and 10ng/mL. By evaluating PSA–AV in the presence of PCa, it could finely improve the problem associated with tPSA: sensitivity in assessing PCa that was relatively low.

Though the PI-RADS v2 is a standard criterion for detecting PCa, it only assesses the appearances on MRI but ignores the capacity of clinical parameters.[24,25] In this study, a crosstab was drawn to evaluate the risk of PCa in different subgroups, and detection rates were calculated. Based on our study, we classified

| Table 4 | The detection rate of PCa stratified by each subgroup of tPSA, PSA–AV, and PI-RADS v2. |
|---------|--------------------------------------------------------------------------------|
| Prostate cancer detection rate, % | |
| PI-RADS v2 | PSA–AV | tPSA (ng/mL) | PSAD (ng/mL/cc) | PSA–AV |
| 1–2 | >250 | 0.0 | 75 | 58.1 |
| 3 | >250 | 0.0 | 12.5 | 25.0 |
| 4–5 | >250 | 0.0 | 100.0 | 50.0 |

PI-RADS v2 = the Prostate Imaging Reporting and Data System version 2; PSA–AV = prostate-specific antigen–age volume; tPSA = total prostate-specific antigen; PSAD = prostate-specific antigen density; PSA = total prostate-specific antigen.

To the best of our knowledge, this study is the first research to assess the PSA–AV in the gray zone with PI-RADS v2 score 3 or serum tPSA 4 to 10ng/mL. The result revealed that of patients in the gray zone, the PSA–AV score was useful in predicting the presence of PCa. Though a PI-RADS v2 score ≤ 3 suggested lower probabilities of PCa, our study showed that a PSA–AV ≤ 250 was helpful in raising the detection rate in this range. The same situation in patients of tPSA levels between 4 and 10ng/mL. By evaluating PSA–AV in the presence of PCa, it could finely improve the problem associated with tPSA: sensitivity in assessing PCa that was relatively low.

Though the PI-RADS v2 is a standard criterion for detecting PCa, it only assesses the appearances on MRI but ignores the capacity of clinical parameters.[24,25] In this study, a crosstab was drawn to evaluate the risk of PCa in different subgroups, and detection rates were calculated. Based on our study, we classified

| Table 5 | The detection rate of PCa stratified by each subgroup of tPSA, PSA–AV, and PI-RADS v2. |
|---------|--------------------------------------------------------------------------------|
| Prostate cancer detection rate, % | |
| PI-RADS v2 | PSA–AV | tPSA (ng/mL) | PSAD (ng/mL/cc) | PSA–AV |
| 1–2 | <0.15 | 13.2 | 0.0 |
| 250 | 0.0 | 75 | 58.1 |
| 3 | <0.15 | 0.0 | 12.5 |
| 250 | 0.0 | 100.0 |
| 4–5 | <0.15 | 25.9 | 0.0 |
| 250 | 0.0 | 100.0 |

PI-RADS v2 = the Prostate Imaging Reporting and Data System version 2; PSA–AV = prostate-specific antigen–age volume; tPSA = total prostate-specific antigen; PSAD = prostate-specific antigen density; PSA = total prostate-specific antigen.
peripheral zone than transition zone. In PI-RADS v2 score 3, the PSA–AV was more efficient in predicting PCa than PSAD, and in tPSA between 4 to 10 ng/mL, the performances of PSA–AV were better than PSA, too. However, the superiority was not enormous.

This study had several limitations. First, our study is retrospective and patient selection bias existed. Pay no attention to the role of extreme values of clinical data. Furthermore, the PI-RADS score was evaluated by 1 radiologist, although he did have 10 years of experience in abdominal imaging. Third, the number of cases was still far from satisfactory. In the future, more cases are needed to balance the number of subgroups. Furthermore, the criteria of parameters classification could be made to be more detailed because the level of serum tPSA is influenced by race, body mass index, and other factors.[28–30]

5. Conclusions

Though PI-RADS v2 performed well in predicting the presence of PCa, in patients of score 3, it needed stricter criteria. Putting serum tPSA and PSA–AV into detecting PCa, patients could be divided into more detailed subgroups of PCa. And in this way, the detection rate of PCa in gray zone may increase.

Author contributions

Conceptualization: Yao Pan.
Data curation: Yuan-Fei Lu, Hai-Yan Chen, Jie-Yu Chen, Cong-Cong Xu.
Formal analysis: Yuan-Fei Lu, Qian Zhang, Cong-Cong Xu.
Funding acquisition: Jian-Xia Xu.
Investigation: Jie-Yu Chen.
Methodology: Qian Zhang, Cong-Cong Xu.
Software: Yao Pan.
Supervision: Yao Pan.
Visualization: Yao Pan, Jian-Xia Xu, Ri-Sheng Yu.
Writing – original draft: Yuan-Fei Lu.
Writing – review & editing: Qian Zhang, Hai-Yan Chen, Jian-Xia Xu, Ri-Sheng Yu.
Ri-Sheng Yu orcid: 0000-0003-0554-9484.

References

[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA: Cancer J Clin 2011;61:69–90.
[2] Zhang K, Bangma CH, Roobol MJ. Prostate cancer screening in Europe and Asia. Asian J Urol 2017;4:86–95.
[3] Hernandez C, Morote J, Minana B, et al. The role of prostate-specific antigen in light of new scientific evidence. Actas Urol Esp 2013;37:324–9.
[4] Chou R, Crosswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762–71.
[5] Eide IA, Angelsen A. Prostate-specific antigen. Tidsskrift Den Norske Lægeforening: Tidsskrift Praktisk Med Ny Raekke 2000;120:2528–31.
[6] Pedler K, Kitzing YX, Varol C, et al. The current status of MRI in prostate cancer. Aust Fam Phys 2015;44:225–30.
[7] Rosenkrantz AB, Babb JS, Taneja SS, et al. Proposed adjustments to PI-RADS Version 2 decision rules: impact on prostate cancer detection. Radiology 2017;283:119–29.
[8] Liddell H, Jyoti R, Hashimolla HZ. mp-MRI prostate characterised. PI-RADS 3 lesions are associated with a low risk of clinically significant prostate cancer - a retrospective review of 92 Biopsied PI-RADS 3 Lesions. Curr Urol 2015;8:96–100.
[9] Brzozowski Appayya M, Sidhu HS, Dikais N, et al. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density. PI-RADS scoring and qualitative descriptors on multiparametric MRI. Br J Radiol 2018;91:20170645.
[10] Patel S, Issa MM, El-Galley R. Evaluation of novel formula of PSA, age, prostate volume, and race in predicting positive prostate biopsy findings. Urology 2013;81:602–6.
[11] Wu YS, Wu XB, Zhang N, et al. Evaluation of PSA-age volume score in predicting prostate cancer in Chinese population. Asian J Androl 2018;20:324–9.
[12] Kasel-Seibert M, Lehmann T, Ahsenbach R, et al. Assessment of PI-RADS v2 for the detection of prostate cancer. Eur J Radiol 2016;85:726–31.
[13] Zhao C, Gao G, Fang D, et al. The efficiency of multiparametric magnetic resonance imaging (mpMRI) using PI-RADS Version 2 in the diagnosis of clinically significant prostate cancer. Clin Imag 2016;40:885–8.
[14] Park SY, Jung DC, Oh YT, et al. Prostate cancer: PI-RADS Version 2 helps preoperatively predict clinically significant cancers. Radiology 2016;280:108–16.
[15] Thai JN, Narayanan HA, George AK, et al. Validation of PI-RADS Version 2 in transition zone lesions for the detection of prostate cancer. Radiology 2018;288:485–91.
[16] Mertan FV, Greer MD, Shih JH, et al. Prospective evaluation of the prostate imaging reporting and Data System Version 2 for prostate cancer detection. J Urol 2016;196:690–6.
[17] Polascik TJ, Oesterling JE, Parini AW. Prostate specific antigen: a decade of discovery—what we have learned and where we are going. J Urol 1999;162:293–306.
[18] Yoshida K, Honda M, Sumi S, et al. Levels of free prostate-specific antigen (PSA) can be selectively measured by heat treatment of serum: free/total-PSA ratios improve detection of prostate carcinoma. Clin Chimic Acta Int J Clin Chem 1999;280:195–203.
[19] Tang P, Du W, Xie K, et al. Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0-10.0 and 10.1-20.0 ng/ml in Chinese men. Urol Oncol 2013;31:744–8.
[20] Savblom C, Malm J, Gowerman A, et al. Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 2005;65:66–72.
[21] Liu ZY, Sun YH, Xu CL, et al. Age-specific PSA reference ranges in Chinese men without prostate cancer. Asian J Androl 2009;11:100–3.
[22] Peng Y, Shen D, Liao S, et al. MRI-based prostate volume-adjusted prostate-specific antigen in the diagnosis of prostate cancer. J Magn Reson Imaging JMRI 2015;42:1733–9.
[23] Coric J, Mucic J, Kucukalic E, et al. Prostate-Specific Antigen (PSA) and prostate volume: better predictor of prostate cancer for bosnian and herzegovina men. Open Biochem J 2015;9:34–6.
[24] Smith CP, Turkley B. PI-RADS v2: current standing and future outlook. Turkish J Urol 2018;44:89–94.
[25] Liu C, Liu SL, Wang ZX, et al. Using the Prostate Imaging Reporting and Data System version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment. Asian J Androl 2018;20:459–64.
[26] DeAntoni EP. Age-specific reference ranges for PSA in the detection of prostate cancer. Oncology (Williston Park, NY) 1997;11:475–82.
[27] Wu TT, Huang JK. The clinical usefulness of prostate-specific antigen (PSA) level and age-specific PSA reference ranges for detecting prostate cancer in Chinese. Urol Int 2004;72:208–11.
[28] Gronkemeier MN, Vollner RT. Predicting prostate biopsy results: the importance of PSA, age, and race. Am J Clin Pathol 2006;126:110–2.
[29] Oh JJ, Jeong SJ, Lee BK, et al. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy. BJU Int 2013;112:E265–71.
[30] Zhou F, Chen X, Pu J, et al. Correlation between body mass index (BMI) and the Gleason score of prostate biopsies in Chinese population. Oncotarget 2016;7:63338–41.